文献速递骨质疏松与代谢性骨病

基线血清PINP与每周两次特立帕肽治疗早期腰椎骨密度增益相关:OASIS队列研究

Baseline serum PINP is associated with early lumbar spine bone mineral density gains during twice-weekly teriparatide treatment: the OASIS cohort study.
PubMed 文献 · Osteoporos Int · 2026-04-06

这项多中心回顾性队列研究纳入242例高骨折风险骨质疏松患者,完成12个月每周两次特立帕肽(28.2 μg)治疗。基线血清PINP独立与腰椎骨密度百分比变化相关(标准化系数=2.73,p<0.001),ROC分析确定基线PINP预测腰椎骨密度增加≥8%的最佳截止值为53.1 μg/L(敏感度74.4%,特异度60.5%,AUC=0.67)。

要点

  • 基线PINP独立预测每周两次特立帕肽12个月腰椎骨密度增益。
  • 基线PINP截止值53.1 μg/L预测腰椎骨密度增加≥8%的AUC为0.67。
  • 41.3%患者12个月时腰椎骨密度增加≥8%,平均变化7.0±8.6%。

核心结论

  • 基线血清PINP是每周两次特立帕肽治疗早期腰椎骨密度反应的临床相关独立预测因素之一。

研究设计与样本

  • 多中心回顾性队列研究,纳入242例高骨折风险骨质疏松患者,完成12个月每周两次特立帕肽(28.2 μg)治疗。

主要发现

  • 腰椎骨密度平均百分比变化为7.0±8.6%,41.3%患者12个月时腰椎骨密度增加≥8%。
  • 多变量模型中,基线总PINP与腰椎骨密度百分比变化显著独立相关(标准化系数=2.73,p<0.001)。
  • ROC分析确定基线PINP预测腰椎骨密度增加≥8%的截止值为53.1 μg/L(敏感度74.4%,特异度60.5%,AUC=0.67)。

关键数值与推荐

  • 基线PINP截止值53.1 μg/L用于预测12个月腰椎骨密度增加≥8%,敏感度74.4%,特异度60.5%,AUC=0.67。

临床怎么用

  • 基线血清PINP可作为接受每周两次特立帕肽治疗的骨质疏松患者早期腰椎骨密度反应的预测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Baseline serum PINP was significantly and independently associated with achieving a ≥ 8% increase in lumbar spine (LS) bone mineral density (BMD) after 12 months of twice-weekly teriparatide therapy. PURPOSE: Early predictors of the BMD response to twice-weekly teriparatide remain poorly defined. This study aimed to identify clinical and biochemical determinants of early LS BMD improvement under this regimen. METHOD: In this retrospective multicenter cohort study, 242 osteoporosis patients at high fracture risk completed 12 months of twice-weekly teriparatide (28.2 μg). At baseline, 88.0% were female, mean age was 80.0 years, 83.5% had a history of osteoporotic fracture, and 72.3% were treatment-naïve. Multivariate regression was performed to identify independent predictors of LS BMD change, and receiver operating characteristic (ROC) analysis was used to determine the optimal cutoff value for predicting an LS BMD increase ≥ 8% at 12 months. RESULTS: The percent change (mean ± standard deviation) in LS BMD was 7.0 ± 8.6%, and 41.3% of patients achieved an LS BMD increase ≥ 8% at 12 months. In the multivariate model, baseline total procollagen type I N-terminal propeptide (PINP) was significantly and independently associated with percent LS BMD change (standardized coefficient = 2.73, p < 0.001). ROC analysis identified a baseline PINP cutoff of 53.1 μg/L for predicting ≥ 8% LS BMD increase (sensitivity 74.4%, specificity 60.5%, area under the curve = 0.67). CONCLUSION: Baseline serum PINP represents one of the clinically relevant independent predictors of early LS BMD response to twice-weekly teriparatide.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Niimi R, Kobayakawa T, Etani Y, et al. Baseline serum PINP is associated with early lumbar spine bone mineral density gains during twice-weekly teriparatide treatment: the OASIS cohort study. Osteoporos Int. 2026. PMID: 41936695. doi:10.1007/s00198-026-07985-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。